HW
BCRX icon

Hancock Whitney’s BioCryst Pharmaceuticals BCRX Stock Holding History

Hancock Whitney’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,190
Closed -$124K – 821
2021
Q1 		$124K Hold
12,190
– – ﹤0.01% 749
2020
Q4 		$91K Buy
+12,190
New +$62.8K ﹤0.01% 774

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Hancock Whitney's BCRX Position: Q2 2021 in Review

Hancock Whitney sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2021, closing a stake of 12,190 shares — an estimated $124K sold.

Hancock Whitney first reported a position in BCRX in Q4 2020 and held it in 2 quarters. The position peaked at $124K in Q1 2021. 195 funds tracked by Wall St. Rank hold BCRX as of Q2 2021.

  • Hancock Whitney reported no remaining BioCryst Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Hancock Whitney sold 12,190 BioCryst Pharmaceuticals shares in Q2 2021, an estimated $124K.
  • Hancock Whitney first reported a position in BioCryst Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Hancock Whitney's BioCryst Pharmaceuticals position peaked at $124K in Q1 2021.
  • 195 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2021.

Based on Hancock Whitney's 13F filing for Q2 2021, filed 9 Aug 2021.